Incidence of most frequent adverse events
| Adverse event . | Placebo, no. (%) N = 30 . | 6 mg senicapoc, no. (%) N = 29 . | 10 mg senicapoc, no. (%) N = 31 . |
|---|---|---|---|
| Diarrhea | 1 (3) | 2 (7) | 5 (16) |
| Nausea | 1 (3) | 3 (10) | 4 (13) |
| Constipation | 1 (3) | 4 (14) | 0 |
| Gastroenteritis | 3 (10) | 0 | 1 (3) |
| Upper respiratory tract infection | 3 (10) | 5 (17) | 1 (3) |
| Chest pain | 0 | 3 (10) | 1 (3) |
| Increased SGOT | 3 (10) | 0 | 1 (3) |
| Arthralgia | 4 (13) | 2 (7) | 3 (10) |
| Back pain | 4 (13) | 4 (14) | 2 (6) |
| Adverse event . | Placebo, no. (%) N = 30 . | 6 mg senicapoc, no. (%) N = 29 . | 10 mg senicapoc, no. (%) N = 31 . |
|---|---|---|---|
| Diarrhea | 1 (3) | 2 (7) | 5 (16) |
| Nausea | 1 (3) | 3 (10) | 4 (13) |
| Constipation | 1 (3) | 4 (14) | 0 |
| Gastroenteritis | 3 (10) | 0 | 1 (3) |
| Upper respiratory tract infection | 3 (10) | 5 (17) | 1 (3) |
| Chest pain | 0 | 3 (10) | 1 (3) |
| Increased SGOT | 3 (10) | 0 | 1 (3) |
| Arthralgia | 4 (13) | 2 (7) | 3 (10) |
| Back pain | 4 (13) | 4 (14) | 2 (6) |
Table lists incidence of treatment-emergent adverse events. Any event that was present in 10% or more of a given dosing group is listed.